(S)-tert-butyl 2-amino-2-oxo-1-phenylethylcarbamate | 437768-38-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-tert-butyl 2-amino-2-oxo-1-phenylethylcarbamate
• 英文别名: tert-butyl N-[carbamoyl(phenyl)methyl]carbamate；tert-butyl N-(2-amino-2-oxo-1-phenylethyl)carbamate
• CAS: 437768-38-2
• 化学式: C₁₃H₁₈N₂O₃
• mdl: MFCD21090866
• 分子量: 250.298
• InChiKey: JPDKWABQKOBPQR-UHFFFAOYSA-N

物化性质

• 沸点：
  432.5±45.0 °C(Predicted)
• 密度：
  1.144±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 2-amino-2-oxo-1-phenylethylcarbamate 在 TEA 、 三氟乙酸酐 作用下， 以 四氢呋喃 为溶剂， 反应 14.0h， 以100%的产率得到(氰基-苯基-甲基)-氨基甲酸叔丁酯
  参考文献：
  名称：

  Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure

  摘要：

  Structure-activity relationships (SAR) of 1 against HCV NS5B polymerase were described. SAR explorations and further structure-based design led to the identifications of 2 and 3 as novel HCV NS5B inhibitors. X-ray structure of 3 in complex with NS5B polymerase was obtained at a resolution of 2.2A, and confirmed the design.

  DOI：

  10.1016/j.bmcl.2006.09.095
• 作为产物：
  描述：

  2-氨基-2-苯基乙酸 在 sodium hydroxide 、 TEA 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 12.5h， 生成 (S)-tert-butyl 2-amino-2-oxo-1-phenylethylcarbamate
  参考文献：
  名称：

  Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure

  摘要：

  Structure-activity relationships (SAR) of 1 against HCV NS5B polymerase were described. SAR explorations and further structure-based design led to the identifications of 2 and 3 as novel HCV NS5B inhibitors. X-ray structure of 3 in complex with NS5B polymerase was obtained at a resolution of 2.2A, and confirmed the design.

  DOI：

  10.1016/j.bmcl.2006.09.095

文献信息

• HCV PROTEASE INHIBITORS AND USES THEREOF
  申请人：Green Brian E.

  公开号：US20100029686A1

  公开（公告）日：2010-02-04

  This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds, salts, and compositions.

  这项发明涉及：(a) 公式I的化合物及其盐，它们可用作丙型肝炎病毒（HCV）抑制剂；(b) 用于制备这种化合物和盐的中间体；(c) 包含这种化合物和盐的药物组合物；以及(d) 使用这种化合物、盐和组合物的方法。
• Nitrile derivatives that inhibit cathepsin K
  申请人：——

  公开号：US20010008901A1

  公开（公告）日：2001-07-19

  Compounds of the formula: 1 wherein R 1 to R 7 and Y are as defined in the specification, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof, are useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, instable angina pectoris, stroke, plaque rupture, transient ischemic attacks, amaurosis fugax, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease.

  该公式化合物：其中R1到R7和Y如规范中定义，并且其药用盐和/或药用酯是用于治疗与半胱氨酸蛋白酶相关的疾病，如骨质疏松症、骨关节炎、类风湿性关节炎、肿瘤转移、肾小球肾炎、动脉粥样硬化、心肌梗死、心绞痛、不稳定性心绞痛、中风、斑块破裂、短暂性缺血性发作、瞬间性视网膜动脉阻塞、外周动脉闭塞性疾病、血管成形术和支架植入术后再狭窄、腹主动脉瘤形成、炎症、自身免疫疾病、疟疾、眼底组织细胞病变和呼吸道疾病的有用化合物。
• N−H Insertion Reactions of Boc-Amino Acid Amides:  Solution- and Solid-Phase Synthesis of Pyrazinones and Pyrazines
  作者：Hana Matsushita、Sang-Hyeup Lee、Kazuhiro Yoshida、Bruce Clapham、Guido Koch、Jürg Zimmermann、Kim D. Janda

  DOI：10.1021/ol047933a

  日期：2004.11.1

  the corresponding pyrazine-6-one products. The pyrazine-6-ones were further derivatized by N-alkylation or by conversion to the arylpyrazines using sequential bromination and Suzuki coupling reactions. [reaction: see text]

  在辛酸铑催化剂存在下，一系列α-重氮-β-酮酸酯与Boc氨基酸酰胺反应。所得的NH插入产物用酸处理，得到1，4-嗪中间体，其被空气氧化以形成相应的吡嗪-6-一产物。使用顺序溴化和Suzuki偶联反应，通过N-烷基化或通过转化为芳基吡嗪，进一步将吡嗪6-酮衍生化。[反应：看文字]
• PYRAZINE KINASE INHIBITORS
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20130131040A1

  公开（公告）日：2013-05-23

  Provided are pyrazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

  提供了用于抑制Syk激酶的吡嗪化合物，用于制备这些化合物的中间体，它们的制备方法，药物组合物，抑制Syk激酶活性的方法，以及治疗至少在一定程度上由Syk激酶活性介导的疾病的方法。
• Beta-amino acid nitrile derivatives as cathepsin K inhibitors
  申请人：——

  公开号：US20020016361A1

  公开（公告）日：2002-02-07

  The present invention relates to beta-amino acid nitrile derivatives and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are cysteine protease inhibitors useful for the treatment of diseases associated with cysteine proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, instable angina pectoris, stroke, plaque rupture, transient ischemic attacks, amaurosis fugax, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease.

  本发明涉及β-氨基酸腈衍生物及其药学上可接受的盐和/或药学上可接受的酯。这些化合物是半胱氨酸蛋白酶抑制剂，可用于治疗与半胱氨酸蛋白酶相关的疾病，如骨质疏松症、骨关节炎、类风湿关节炎、肿瘤转移、肾小球肾炎、动脉粥样硬化、心肌梗死、心绞痛、不稳定性心绞痛、中风、斑块破裂、短暂性缺血性发作、暂时性视网膜动脉阻塞、外周动脉闭塞症、血管成形术和支架植入术后再狭窄、腹主动脉瘤形成、炎症、自身免疫疾病、疟疾、眼底组织细胞病变和呼吸系统疾病。